Background screening provider First Advantage (NASDAQ:FA) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 36.8% year on year to $420 million. The company’s full-year revenue guidance of $1.66 billion at the midpoint came in 2.4% above analysts’ estimates. Its non-GAAP profit of $0.30 per share was 13.7% above analysts’ consensus estimates.
Footwear conglomerate Wolverine Worldwide (NYSE:WWW) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 4.6% year on year to $517.5 million. The company’s full-year revenue guidance of $1.97 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $0.45 per share was 3.1% above analysts’ consensus estimates.
Medical device company Integra LifeSciences (NASDAQ:IART) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.7% year on year to $434.9 million. On the other hand, next quarter’s revenue guidance of $382.5 million was less impressive, coming in 2.8% below analysts’ estimates. Its non-GAAP profit of $0.83 per share was 3.7% above analysts’ consensus estimates.
March S&P 500 E-Mini futures (ESH26) are down -0.05%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.09% this morning, pointing to a muted open on Wall Street as investors digest earnings from AI bellwether Nvidia, while nuclear talks betwee...
Aerospace and defense company Ducommun (NYSE:DCO) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 9.4% year on year to $215.8 million. Its non-GAAP profit of $1.05 per share was 8.9% above analysts’ consensus estimates.
Clinical research company Fortrea Holdings (NASDAQ:FTRE) fell short of the market’s revenue expectations in Q4 CY2025, with sales falling 5.2% year on year to $660.5 million. The company’s full-year revenue guidance of $2.6 billion at the midpoint came in 4.9% below analysts’ estimates. Its non-GAAP profit of $0.09 per share was 43.8% below analysts’ consensus estimates.
The economist added that the Federal Open Market Committee’s structure makes it susceptible to groupthink and that the institution has experienced mission creep.
Commercial real estate finance company Walker & Dunlop (NYSE:WD) fell short of the market’s revenue expectations in Q4 CY2025, with sales flat year on year at $340 million. Its non-GAAP profit of $0.28 per share was 80.8% below analysts’ consensus estimates.
The latest prediction market odds for the winner of the WBD acquisition saga come after Paramount raised its takeover offer to $31 per share, up from $30 per share.
Medical technology company Enovis Corporation (NYSE:ENOV) fell short of the market’s revenue expectations in Q4 CY2025 as sales rose 2.6% year on year to $575.8 million. The company’s full-year revenue guidance of $2.34 billion at the midpoint came in 0.7% below analysts’ estimates. Its non-GAAP profit of $0.95 per share was 13.1% above analysts’ consensus estimates.
Healthcare tech company Privia Health Group (NASDAQ:PRVA) announced better-than-expected revenue in Q4 CY2025, with sales up 17.4% year on year to $541.2 million. The company’s full-year revenue guidance of $2.4 billion at the midpoint came in 3.7% above analysts’ estimates. Its non-GAAP profit of $0.25 per share was 30.2% above analysts’ consensus estimates.
Filtration equipment manufacturer Donaldson (NYSE:DCI) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 3% year on year to $896.3 million. Its non-GAAP profit of $0.83 per share was 6.6% below analysts’ consensus estimates.
Energy drink company Celsius (NASDAQ:CELH) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 117% year on year to $721.6 million. Its non-GAAP profit of $0.26 per share was 36.9% above analysts’ consensus estimates.
Luxury furniture retailer Arhaus (NASDAQ:ARHS) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.1% year on year to $364.8 million. On the other hand, next quarter’s revenue guidance of $310 million was less impressive, coming in 5% below analysts’ estimates. Its GAAP profit of $0.11 per share was 15.8% above analysts’ consensus estimates.
